Rajesh Kannangai
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Rajesh Kannangai has a total of 157 co-authors. Here are the top co-authors by number of shared publications:
- Priya Abraham
Department of Clinical Virology, Christian Medical College, Vellore, Tamil Nadu, India
7 shared publications Gnanadurai John Fletcher
Department of Virology, Christian Medical College, Vellore, Tamil Nadu, India
6 shared publications- Gnanadurai John Fletcher
Department of Clinical Virology, Christian Medical College, Vellore, Tamil Nadu, India
6 shared publications John Paul Demosthenes
Department of Virology, Christian Medical College, Vellore, Tamil Nadu, India
6 shared publicationsJaiprasath Sachithanandham
Department of Clinical Virology, Christian Medical College, Vellore, Tamil Nadu, 632004, India
5 shared publicationsPriya Abraham
Department of Virology, Christian Medical College, Vellore, Tamil Nadu, India
5 shared publications
Latest Publications
- 25 June 2026
- Published by Springer Nature in Cancer Causes & Control
- Vol. 37 (7)
Serum human papilloma virus detection following treatment of cervical cancer: prevalence and its correlation with recurrence
The detection of human papilloma virus (HPV) in serum after treatment for cervical cancer warrants further investigation. To study the prevalence of serum HPV and correlate its presence with cervical cancer recurrence. This prospective cross-sectional study recruited 100 patients following treatment of HPV-associated cervical cancer between January 2023 and March 2024 at a tertiary care centre in South India. Patients who had completed treatment within the past 3 years were included. After obtaining consent, a one-time serum sample for HPV detection was analysed using a multiplex real-time PCR AnyplexTM II HPV HR detection assay (Seegene, Seoul, South Korea). The prevalence of serum HPV was correlated with disease recurrence and evaluated by Fisher's Exact test. The log-rank test assessed the differences in disease-free survival between cases with and without measurable serum HPV. Among the 100 patients, the prevalence of serum HPV was 18% (18/100), with genotype 16 being found in 83.3% (15/18) of cases. There were 27 recurrences, of which 15 (55.6%) had detectable serum HPV DNA. Disease recurrence was significantly associated with serum HPV (odds ratio: 29.17, 95% confidence interval: 7.32-116.24). Higher serum HPV DNA levels, as determined by semi-quantification (2 + and 3 +), were associated with an increased hazard ratio for recurrence (58.33, CI: 6.83-498.23). Kaplan-Meier disease-free estimates revealed a significant association between recurrence and serum HPV prevalence (p = 0.000). Serum HPV can be used in the detection of recurrence in post-treatment surveillance of cervical cancer and should be validated in a prospective, longitudinal study.
- 25 June 2026
- Published by Springer Nature in Cancer Causes & Control
- Vol. 37 (7)
Serum human papilloma virus detection following treatment of cervical cancer: prevalence and its correlation with recurrence
The detection of human papilloma virus (HPV) in serum after treatment for cervical cancer warrants further investigation. To study the prevalence of serum HPV and correlate its presence with cervical cancer recurrence. This prospective cross-sectional study recruited 100 patients following treatment of HPV-associated cervical cancer between January 2023 and March 2024 at a tertiary care centre in South India. Patients who had completed treatment within the past 3 years were included. After obtaining consent, a one-time serum sample for HPV detection was analysed using a multiplex real-time PCR AnyplexTM II HPV HR detection assay (Seegene, Seoul, South Korea). The prevalence of serum HPV was correlated with disease recurrence and evaluated by Fisher's Exact test. The log-rank test assessed the differences in disease-free survival between cases with and without measurable serum HPV. Among the 100 patients, the prevalence of serum HPV was 18% (18/100), with genotype 16 being found in 83.3% (15/18) of cases. There were 27 recurrences, of which 15 (55.6%) had detectable serum HPV DNA. Disease recurrence was significantly associated with serum HPV (odds ratio: 29.17, 95% confidence interval: 7.32-116.24). Higher serum HPV DNA levels, as determined by semi-quantification (2 + and 3 +), were associated with an increased hazard ratio for recurrence (58.33, CI: 6.83-498.23). Kaplan-Meier disease-free estimates revealed a significant association between recurrence and serum HPV prevalence (p = 0.000). Serum HPV can be used in the detection of recurrence in post-treatment surveillance of cervical cancer and should be validated in a prospective, longitudinal study.
- Open Access
- 19 March 2026
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 167, 108542
Paradoxical reactions in patients with tuberculous lymphadenitis: A pilot immunopathogenic study
- 19 March 2026
- Published by Elsevier in International Journal of Infectious Diseases
- Vol. 167, 108542
Open AccessParadoxical reactions in patients with tuberculous lymphadenitis: A pilot immunopathogenic study
- Open Access
- 1 January 2026
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 37
Comparative performance of first-void urine and self-collected vaginal swabs against clinician-collected cervical samples using 2 HPV real-time assays in Indian women
To enhance participation of women in cervical cancer (CC) screening, we compared high-risk human papillomavirus (HR-HPV) DNA testing of first-void urine (FVU) and self-collected vaginal swabs (SCVSs) to the gold standard clinician collected cervical specimens (CCCSs). In this cross-sectional study, consecutive consenting women (n=295) identified for CC screening mainly from Gynaecology-Oncology out-patient clinics were enrolled from May to October 2024. All were educated to provide self-samples (FVU, SCVS) followed by CCCS. All samples were tested for HR-HPV by 2 real-time polymerase chain reaction assays: Alinity m HR-HPV assay and Allplex™ II HPV HR assay. Awareness of CC, its screening, prevention and acceptability of self-sampling methods were assessed through a questionnaire. All sample types showed identical concordance (93.9%)/discordance (6.1%) across both real-time assays. Using Alinity m, sensitivity and specificity of FVU vs. CCCS was similar to SCVS vs. CCCS, i.e., 83.3% (95% confidence interval [CI]=68.64%-93.03%) and 98% (95% CI=95.45%-99.36%) respectively. With Allplex, sensitivity and specificity of FVU vs. CCCS was 84.78% (95% CI=71.13%-93.66%) and 97.19% (95% CI=94.29%-98.86%) respectively; and that of SCVS vs. CCCS was 97.83% (95% CI=88.47%-99.94%) and 95.98% (95% CI=92.74%-98.06%) respectively. Majority were unaware of CC (86.4%), its screening (98.6%) or its prevention (96.9%). Majority of women (92%) preferred FVU for CC if screened at regular intervals. This study shows a favorable performance of FVU and SCVS in both assays. FVU is a scalable, non-invasive, acceptable and feasible alternative to CCCS, with the potential to intensify CC screening programs in low- and middle-income countries.
- 1 January 2026
- Published by XMLink in Journal of Gynecologic Oncology
- Vol. 37
Open AccessComparative performance of first-void urine and self-collected vaginal swabs against clinician-collected cervical samples using 2 HPV real-time assays in Indian women
To enhance participation of women in cervical cancer (CC) screening, we compared high-risk human papillomavirus (HR-HPV) DNA testing of first-void urine (FVU) and self-collected vaginal swabs (SCVSs) to the gold standard clinician collected cervical specimens (CCCSs). In this cross-sectional study, consecutive consenting women (n=295) identified for CC screening mainly from Gynaecology-Oncology out-patient clinics were enrolled from May to October 2024. All were educated to provide self-samples (FVU, SCVS) followed by CCCS. All samples were tested for HR-HPV by 2 real-time polymerase chain reaction assays: Alinity m HR-HPV assay and Allplex™ II HPV HR assay. Awareness of CC, its screening, prevention and acceptability of self-sampling methods were assessed through a questionnaire. All sample types showed identical concordance (93.9%)/discordance (6.1%) across both real-time assays. Using Alinity m, sensitivity and specificity of FVU vs. CCCS was similar to SCVS vs. CCCS, i.e., 83.3% (95% confidence interval [CI]=68.64%-93.03%) and 98% (95% CI=95.45%-99.36%) respectively. With Allplex, sensitivity and specificity of FVU vs. CCCS was 84.78% (95% CI=71.13%-93.66%) and 97.19% (95% CI=94.29%-98.86%) respectively; and that of SCVS vs. CCCS was 97.83% (95% CI=88.47%-99.94%) and 95.98% (95% CI=92.74%-98.06%) respectively. Majority were unaware of CC (86.4%), its screening (98.6%) or its prevention (96.9%). Majority of women (92%) preferred FVU for CC if screened at regular intervals. This study shows a favorable performance of FVU and SCVS in both assays. FVU is a scalable, non-invasive, acceptable and feasible alternative to CCCS, with the potential to intensify CC screening programs in low- and middle-income countries.
- 29 December 2025
- Published by SAGE Publications in AIDS Research and Human Retroviruses
- Vol. 42 (2) , 67-76
Comparison of Plasma, Dried Blood Spots, and Peripheral Blood Mononuclear Cells as Biosamples for HIV-1 Genotypic Drug Resistance in a Tertiary Care Center
The collection, storage, and transport of plasma, the ideal specimen for HIV-1 genotyping, is plagued by technical difficulties in resource-limited settings. We aimed to compare corresponding bio-samples for HIV-1 genotypic drug resistance testing. A total of 87 matched specimens of plasma, dried blood spots (DBS), and peripheral blood mononuclear cells (PBMCs) collected from 29 persons living with HIV (PLWH) in clinical, immunological, and/or virological failure were included. Drug resistance genotyping was done by nested PCR amplification and Sanger sequencing of the HIV-1 pol gene. The clinical reporting was based on the Stanford University HIV Drug Resistance Database. Amplification and genotyping success rates from the three sample types were compared. The level of agreement between the sample types was assessed using Cohen’s kappa coefficient. In total, 89.7% ( n = 26) of samples were amplified in plasma, 69% ( n = 20) in DBS, and 100% ( n = 29) in PBMC. In samples with plasma viral load >1,000 copies/mL, 96.2% were amplified in plasma, 73.1% in DBS, and 100% in PBMCs. The median number of mutations detected in plasma, DBS, and PBMCs was 6.5 (interquartile range [IQR]: 2–8.25), 5 (IQR: 0–6), and 5 (IQR: 2–7), respectively. The difference in the number of mutations across the three sample types was not statistically significant ( p = 0.221). The agreement between the sample types was calculated based on susceptibility and resistance to different antivirals. The kappa values for nucleoside reverse transcriptase inhibitors and non-nucleoside reverse transcriptase inhibitors ranged from 0.70 to 0.88 and 0.75 to 0.87, respectively. Six samples showed discordance in HIV-1 drug resistance profiles when compared across the three compartments. DBS is a promising alternative to plasma for HIV-1 genotypic testing in resource-limited settings owing to the ease of sampling, storage, transportation, human resource efficiency, and cost-effectiveness. However, no single specimen type can satisfy all requirements and purposes. Selecting an appropriate specimen for a setting requires careful consideration of the practical constraints, logistical capacity, and application needs.
- 29 December 2025
- Published by SAGE Publications in AIDS Research and Human Retroviruses
- Vol. 42 (2) , 67-76
Comparison of Plasma, Dried Blood Spots, and Peripheral Blood Mononuclear Cells as Biosamples for HIV-1 Genotypic Drug Resistance in a Tertiary Care Center
The collection, storage, and transport of plasma, the ideal specimen for HIV-1 genotyping, is plagued by technical difficulties in resource-limited settings. We aimed to compare corresponding bio-samples for HIV-1 genotypic drug resistance testing. A total of 87 matched specimens of plasma, dried blood spots (DBS), and peripheral blood mononuclear cells (PBMCs) collected from 29 persons living with HIV (PLWH) in clinical, immunological, and/or virological failure were included. Drug resistance genotyping was done by nested PCR amplification and Sanger sequencing of the HIV-1 pol gene. The clinical reporting was based on the Stanford University HIV Drug Resistance Database. Amplification and genotyping success rates from the three sample types were compared. The level of agreement between the sample types was assessed using Cohen’s kappa coefficient. In total, 89.7% ( n = 26) of samples were amplified in plasma, 69% ( n = 20) in DBS, and 100% ( n = 29) in PBMC. In samples with plasma viral load >1,000 copies/mL, 96.2% were amplified in plasma, 73.1% in DBS, and 100% in PBMCs. The median number of mutations detected in plasma, DBS, and PBMCs was 6.5 (interquartile range [IQR]: 2–8.25), 5 (IQR: 0–6), and 5 (IQR: 2–7), respectively. The difference in the number of mutations across the three sample types was not statistically significant ( p = 0.221). The agreement between the sample types was calculated based on susceptibility and resistance to different antivirals. The kappa values for nucleoside reverse transcriptase inhibitors and non-nucleoside reverse transcriptase inhibitors ranged from 0.70 to 0.88 and 0.75 to 0.87, respectively. Six samples showed discordance in HIV-1 drug resistance profiles when compared across the three compartments. DBS is a promising alternative to plasma for HIV-1 genotypic testing in resource-limited settings owing to the ease of sampling, storage, transportation, human resource efficiency, and cost-effectiveness. However, no single specimen type can satisfy all requirements and purposes. Selecting an appropriate specimen for a setting requires careful consideration of the practical constraints, logistical capacity, and application needs.
- 3 June 2025
- Published by Elsevier in Indian Journal of Medical Microbiology
- Vol. 56, 100885
HIV vaccine – Is there a ray of hope in the rugged journey?
- 3 June 2025
- Published by Elsevier in Indian Journal of Medical Microbiology
- Vol. 56, 100885
HIV vaccine – Is there a ray of hope in the rugged journey?
- 31 May 2025
- Published by Elsevier in Computational Biology and Chemistry
- Vol. 119, 108536
Mutational dynamics and phylogenetic insights into monkeypox virus clade I evolution
- 31 May 2025
- Published by Elsevier in Computational Biology and Chemistry
- Vol. 119, 108536
Mutational dynamics and phylogenetic insights into monkeypox virus clade I evolution
- 21 April 2025
- Published by Elsevier in Indian Journal of Medical Microbiology
- Vol. 55, 100853
First Human Parechovirus CNS infections from India: a report of two cases
- 21 April 2025
- Published by Elsevier in Indian Journal of Medical Microbiology
- Vol. 55, 100853
First Human Parechovirus CNS infections from India: a report of two cases
- 10 April 2025
- Published by Elsevier in Indian Journal of Medical Microbiology
- Vol. 55, 100847
HPV vaccines – A game changer for preventing HPV-related cancers
- 10 April 2025
- Published by Elsevier in Indian Journal of Medical Microbiology
- Vol. 55, 100847
HPV vaccines – A game changer for preventing HPV-related cancers
- Open Access
Clinical and immunological predictors of paradoxical reactions in patients with tuberculous lymphadenitis
Background & Aim Tuberculous paradoxical reaction in HIV-negative patients is rare and not well understood. This study aimed to determine the incidence of paradoxical reaction and identify clinical and immunological predictors contributing to its development. Methods Patients with tuberculous lymphadenitis on anti-tuberculous therapy were monitored for paradoxical reaction. Clinical, histopathological, microbiological, and immunological parameters of paradoxical reaction (n=10) and no paradoxical reaction (n=66) groups were analysed at baseline, 2 months, and 6 months. Peripheral blood mononuclear cells from paradoxical reaction (n=9) and no paradoxical reaction (n=13) patients were stimulated with TB-ESAT peptide, and mRNA expressions of cytokines (IL-4, IL-10, IL-12, TNF-α, IFN-γ) and transcription factors (T-bet, GATA-3) were quantified. Results Paradoxical reaction incidence was 5.7% (4/70); six patients presented with paradoxical reaction at baseline. The mean paradoxical reaction onset was 3.25 months. Absence of necrosis at baseline was a significant predictor (OR: 0.069; p=0.039). IL-10 mRNA at 2 months and IL-12 mRNA at 6 months increased in the paradoxical reaction compared to no paradoxical reaction (p=0.05). In paradoxical reaction, baseline T-bet mRNA correlated with IFN-γ (r=0.79, pConclusion Differential Th1/Th2 regulation driven by transcriptional factors alters cytokine expression, influencing paradoxical reaction. Further transcriptomic/proteomic studies are needed to elucidate immune mechanisms for precise therapeutic intervention.
Open AccessClinical and immunological predictors of paradoxical reactions in patients with tuberculous lymphadenitis
Background & Aim Tuberculous paradoxical reaction in HIV-negative patients is rare and not well understood. This study aimed to determine the incidence of paradoxical reaction and identify clinical and immunological predictors contributing to its development. Methods Patients with tuberculous lymphadenitis on anti-tuberculous therapy were monitored for paradoxical reaction. Clinical, histopathological, microbiological, and immunological parameters of paradoxical reaction (n=10) and no paradoxical reaction (n=66) groups were analysed at baseline, 2 months, and 6 months. Peripheral blood mononuclear cells from paradoxical reaction (n=9) and no paradoxical reaction (n=13) patients were stimulated with TB-ESAT peptide, and mRNA expressions of cytokines (IL-4, IL-10, IL-12, TNF-α, IFN-γ) and transcription factors (T-bet, GATA-3) were quantified. Results Paradoxical reaction incidence was 5.7% (4/70); six patients presented with paradoxical reaction at baseline. The mean paradoxical reaction onset was 3.25 months. Absence of necrosis at baseline was a significant predictor (OR: 0.069; p=0.039). IL-10 mRNA at 2 months and IL-12 mRNA at 6 months increased in the paradoxical reaction compared to no paradoxical reaction (p=0.05). In paradoxical reaction, baseline T-bet mRNA correlated with IFN-γ (r=0.79, pConclusion Differential Th1/Th2 regulation driven by transcriptional factors alters cytokine expression, influencing paradoxical reaction. Further transcriptomic/proteomic studies are needed to elucidate immune mechanisms for precise therapeutic intervention.
- 18 March 2025
- Published by Wiley in Journal of Medical Virology
- Vol. 97 (3) , e70307
Superior Performance of Newly Developed Alinity Anti‐HCV Next Assay in the Diagnosis of HCV Infection
World Health Organization recommends anti‐HCV antibody testing for primary screening to be followed by HCV‐RNA. However, current serological assays are prone to false‐positive results. We ascertained the ability of the newly developed Abbott Alinity‐i anti‐HCV Next assay (Research‐Use‐Only) to resolve false‐positives and profiled its performance edges. Samples ( n = 2186) received from January to June 2024 were subjected to anti‐HCV testing using Architect and anti‐HCV Next (Abbott), and LIAISON XL MUREX HCV antibody assays. Samples were categorized based on the signal to cutoff (S/CO) of on‐market anti‐HCV assays (Architect and Liaison) as negative Architect ( n = 1537), equivocal Architect ≥1/Liaison‐ ( n = 226), low‐positive Architect+ ≥1 to ( n = 228) and high‐positive Architect ≥8/Liaison+ ( n = 195). Hepatitis C virus core antigen (HCVcAg) and HCV‐RNA were quantified using Architect HCVcAg and Abbott real‐time PCR, respectively. Performance on seroconversion and proficiency testing panels were assessed. Significant proportion of equivocal (99%) & low‐positive (76.3%) samples were negative in Next ( p < 0.0001). The signal intensities of Next were significantly lower for true‐negative and higher for positives than the other two assays ( p < 0.0001). Next exhibited superior (10–12 days) seroconversion sensitivity (2/4 panels) and comparable performance between genotypes ( p > 0.05). Our findings suggest that the newly developed anti‐HCV Next assay is configured better to resolve challenging false‐positives and to achieve exquisite sensitivity, thereby reducing the burden/cost of retesting and expensive reflex testing for the effective cascade of care.
- 18 March 2025
- Published by Wiley in Journal of Medical Virology
- Vol. 97 (3) , e70307
Superior Performance of Newly Developed Alinity Anti‐HCV Next Assay in the Diagnosis of HCV Infection
World Health Organization recommends anti‐HCV antibody testing for primary screening to be followed by HCV‐RNA. However, current serological assays are prone to false‐positive results. We ascertained the ability of the newly developed Abbott Alinity‐i anti‐HCV Next assay (Research‐Use‐Only) to resolve false‐positives and profiled its performance edges. Samples ( n = 2186) received from January to June 2024 were subjected to anti‐HCV testing using Architect and anti‐HCV Next (Abbott), and LIAISON XL MUREX HCV antibody assays. Samples were categorized based on the signal to cutoff (S/CO) of on‐market anti‐HCV assays (Architect and Liaison) as negative Architect ( n = 1537), equivocal Architect ≥1/Liaison‐ ( n = 226), low‐positive Architect+ ≥1 to ( n = 228) and high‐positive Architect ≥8/Liaison+ ( n = 195). Hepatitis C virus core antigen (HCVcAg) and HCV‐RNA were quantified using Architect HCVcAg and Abbott real‐time PCR, respectively. Performance on seroconversion and proficiency testing panels were assessed. Significant proportion of equivocal (99%) & low‐positive (76.3%) samples were negative in Next ( p < 0.0001). The signal intensities of Next were significantly lower for true‐negative and higher for positives than the other two assays ( p < 0.0001). Next exhibited superior (10–12 days) seroconversion sensitivity (2/4 panels) and comparable performance between genotypes ( p > 0.05). Our findings suggest that the newly developed anti‐HCV Next assay is configured better to resolve challenging false‐positives and to achieve exquisite sensitivity, thereby reducing the burden/cost of retesting and expensive reflex testing for the effective cascade of care.